2017
Retention in medication-assisted treatment programs in Ukraine—Identifying factors contributing to a continuing HIV epidemic
Dumchev K, Dvoryak S, Chernova O, Morozova O, Altice FL. Retention in medication-assisted treatment programs in Ukraine—Identifying factors contributing to a continuing HIV epidemic. International Journal Of Drug Policy 2017, 48: 44-53. PMID: 28800420, PMCID: PMC5603251, DOI: 10.1016/j.drugpo.2017.05.014.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentMedication-assisted treatment programTB test resultsTwelve-month retentionCare delivery systemCorrelates of retentionEvidence-based strategiesTB patientsMultivariable analysisOpioid dependenceAgonist treatmentHIV transmissionClinical recordsHIV epidemicOAT programsPatient retentionHigher dosingHigh dosesTreatment programPatientsSurvival analysis methodsDosingTuberculosisElectronic monitoring systemTreatment
2011
Hepatic Safety and Lack of Antiretroviral Interactions With Buprenorphine/Naloxone in HIV-Infected Opioid-Dependent Patients
Vergara-Rodriguez P, Tozzi MJ, Botsko M, Nandi V, Altice F, Egan JE, O'Connor PG, Sullivan LE, Fiellin DA. Hepatic Safety and Lack of Antiretroviral Interactions With Buprenorphine/Naloxone in HIV-Infected Opioid-Dependent Patients. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s62-s67. PMID: 21317596, DOI: 10.1097/qai.0b013e31820a820f.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneOpioid-dependent patientsMedian aspartate aminotransferasePharmacodynamic interactionsAspartate aminotransferaseBup/ALT valuesAlanine aminotransferaseBUP/NXOpioid-dependent HIVProspective cohort studyHepatic safetyHepatitis CCohort studyHepatic toxicityHIVPatientsAtazanavirNaloxonePrior reportsExposure measuresSignificant decreaseAminotransferaseSignificant changesTreatment
2010
DAART for Human Immunodeficiency Virus–Infected Patients: Studying Subjects Not at Risk for Nonadherence and Use of Untested Interventions
Altice FL, Springer SA. DAART for Human Immunodeficiency Virus–Infected Patients: Studying Subjects Not at Risk for Nonadherence and Use of Untested Interventions. JAMA Internal Medicine 2010, 170: 109-110. PMID: 20065210, PMCID: PMC2825565, DOI: 10.1001/archinternmed.2009.459.Peer-Reviewed Original ResearchMeSH KeywordsAdenineAdministration, OralAdolescentAdultAgedAnti-HIV AgentsDeoxycytidineDose-Response Relationship, DrugDrug Resistance, ViralEmtricitabineFemaleGenotypeHIV InfectionsHIV-1HumansLopinavirMaleMiddle AgedOrganophosphonatesPatient CompliancePyrimidinonesRandomized Controlled Trials as TopicRNA, ViralStavudineTenofovirTreatment OutcomeYoung Adult
2006
The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention
Altice FL, Sullivan LE, Smith-Rohrberg D, Basu S, Stancliff S, Eldred L. The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention. Clinical Infectious Diseases 2006, 43: s178-s183. PMID: 17109304, DOI: 10.1086/508181.Peer-Reviewed Original ResearchMeSH KeywordsBuprenorphineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHIV InfectionsHumansIncidenceMaleNarcotic AntagonistsOpioid-Related DisordersRisk AssessmentSeverity of Illness IndexSubstance Abuse DetectionSubstance Abuse Treatment CentersSurvival AnalysisTreatment OutcomeUnited StatesConceptsHIV clinical care settingsHIV treatment outcomesClinical care settingsRole of buprenorphineOpioid dependenceTreatment outcomesCare settingsHuman immunodeficiency virus (HIV) infectionStudies of buprenorphineImmunodeficiency virus infectionHIV infection preventionUntreated opioid dependenceAntiretroviral therapyHIV carePreventive therapySecondary preventionAntiretroviral treatmentBuprenorphine treatmentHIV infectionOpportunistic infectionsSuccessful treatmentInfection preventionVirus infectionBuprenorphineInfected individuals